![\"\"](\"\/cbr\/files\/2026\/06\/IMG_9403-1024x683.jpg\")
<\/p>\n
AI is rapidly reshaping how we understand, diagnose, and treat the brain at a moment when aging populations are placing unprecedented strain on healthcare systems. To address this shift, Boston University and the BU Center for Brain Recovery<\/a> hosted an expert panel discussion that convened leaders from academia, healthcare, and industry to explore how AI is driving real progress in brain health from early detection to digital therapeutics and emerging neurotechnology.<\/p>\n Held as part of the first-ever Boston Tech Week<\/a>, this event brought together over 100 attendees from academia, industry, healthcare, and startups across the Boston area and beyond. Given the panel’s diverse expertise across academia, hospital systems, startups, and deep learning, the questions were designed to surface productive tension between what the technology can do and what the healthcare system is actually ready to adopt.<\/p>\n Watch the Panel Discussion on YouTube<\/a><\/p>\n The following 10 key takeaways reflect the insights and perspectives shared by the panelists throughout the discussion.<\/p>\n Mylea Charvat, PhD<\/a> Andy Palmer, MBA<\/a> Bernardo Bizzo, MD-PhD<\/a> Marisa Krummrich, MS<\/a> Oliver Armitage, PhD<\/a> Swathi Kiran, PhD<\/a> <\/div><\/span><\/span><\/p>\n AI is enabling earlier identification of risk for neurological disorders by uncovering patterns in large datasets, with the potential to detect signals before symptoms appear.<\/p>\n Digital tools and AI-driven technologies are moving brain health assessment and care out of the clinic and into patients\u2019 everyday lives, into their hands and their homes.<\/p>\n The bottleneck isn’t the amount of data available, but whether it’s properly structured.\u00a0 LLMs are now being used to extract and structure insights buried in clinical notes, unlocking previously untapped information. effectively at the point of care for patients.<\/p>\n Traditional in-clinic cognitive testing is being replaced by scalable, digital approaches that capture richer, real-time behavioral data.<\/p>\n The clearest real-world adoption of AI (e.g., seizure detection in under-resourced hospitals) happened because it replaced a staffing gap, not because it was technically impressive which is a critical lesson for product design.<\/p>\n AI models that perform well in controlled research settings often struggle to generalize across diverse patients in real-world environments. In testing, these tools need to be exposed to different types of data.<\/p>\n Passive signals from devices from that range from typing patterns, voice-to-text errors, and speech pauses hold significant diagnostic potential, but we lack the frameworks to extract and clinically validate that data<\/p>\n Doctors won’t use AI tools they can’t see inside, so models need to be able to explain reasoning and point to evidence to support claims. Explainability is not a nice-to have but a prerequisite for adoption in clinical settings.<\/p>\n In addition to strong technical performance, successful innovation depends on strong product-market fit, human centered design, and building trust with both patients and doctors.<\/p>\n No two human brains are alike, and the panel agreed that AI’s ultimate promise is moving medicine away from treating statistical averages toward truly personalized, continuously monitored brain health care.<\/p>\n <\/p>\n Keep in Touch<\/strong> Support our Work Learn More about our Industry Partner Program Watch the Full Panel
\nThe discussion spanned four core themes: 1) early detection and diagnosis, 2) digital therapeutics and neurotechnology, 3) real-world clinical adoption, and 4) regulation and health equity; each chosen to move the conversation from early promise to practical reality. These themes reflect the full journey of an AI-driven brain health innovation lifecycle. From the research lab and training data, through clinical validation and regulatory approval, and ultimately into the hands of patients and providers.<\/p>\n10 Key Takeaways<\/h2>\n
Panelists<\/span><\/h2>\n
\nFractional CMO; Founder, Savonix<\/p>\n
\nEntrepreneur & Co-founder, Liza Health<\/p>\n
\nSenior Director, Mass General Brigham AI<\/p>\n
\nDeep Learning & Healthcare, MIT<\/p>\n
\nChief Clinical & Data Officer, Axoft<\/p>\nModerator<\/span><\/h2>\n
\nJames and Cecilia Tse Ying Professor in Neurorehabilitation, Boston University; Co-founder, Constant Therapy<\/p>\n1. Earlier detection is the biggest area of opportunity<\/span><\/h3>\n
2. Bringing science closer to the people<\/span><\/h3>\n
3. Powerful data requires structuring<\/span><\/h3>\n
4. Cognitive assessment is undergoing a major shift<\/span><\/h3>\n
5. AI succeeds clinically when it reduces burden, not adds to it<\/span><\/h3>\n
6. Performance in the lab doesn\u2019t guarantee clinical success<\/span><\/h3>\n
7. Smartphones already know more about brain health than most doctors.<\/span><\/h3>\n
8. Clinician trust is critical<\/span><\/h3>\n
9. Entrepreneurship in this field requires more than just strong science<\/span><\/h3>\n
10. The field is moving toward precision brain health<\/span><\/h3>\n
\nStay Connected<\/h2>\n
\nIf you would like to stay informed about future BU Center for Brain Recovery events and opportunities like this one,\u00a0<\/span>connect with us on LinkedIn<\/a>\u00a0<\/span>and\u00a0<\/span>subscribe to our newsletter<\/a>.<\/p>\n
\n<\/strong>Our Center is committed to improving the lives of individuals affected by neurological disorders through innovative research and collaborative care. The generosity of individual donors helps accelerate treatments and expand our impact. You can directly support our work by donating today<\/a>.<\/p>\n
\n<\/strong>If your company is interested in potentially partnering with the BU Center for Brain Recovery, let us know via our partnership form<\/a>, and someone from our team will be in touch with you.<\/p>\n
\n<\/strong>To hear the complete discussion and explore these ideas in greater depth, watch the full panel<\/a>.<\/p>\n